ATM is the most common somatic mutation in MCL (~40-50%). Not directly therapy-selecting;...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-ATM-LOSS-MCL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MCL |
| Sources | SRC-CIVIC SRC-ESMO-MCL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | ATM loss-of-function (mutation or 11q deletion) |
| Disease | DIS-MCL |
| ESCAT tier | IIA |
| Recommended combinations | standard MCL therapy by fitness (BTKi, R-CHOP/R-DHAP+ASCT, BR), ATR inhibitor in trial (experimental) |
| Evidence summary | ATM is the most common somatic mutation in MCL (~40-50%). Not directly therapy-selecting; standard MCL regimens (BTKi, R-CHOP/R-DHAP induction + ASCT, BR) apply. ATM loss may sensitize to ATR inhibitors in trials. ESCAT IIA (biological) / OncoKB Level 3A. |
Notes
Concurrent TP53 mutation is the dominant adverse prognostic in MCL; isolated ATM is less prognostic.
Used By
No reverse references found in the YAML corpus.